A Phase 2 interventional study of Denosumab and Zoledronic acid in Non-Small Cell Lung Cancer, sponsored by Amgen. Completed at 74 sites in 10 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 2, and was the 23rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 11 more countries
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 35 more countries
Ages 18–100
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 8 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 145 across the 31 interventional studies, 102 across the 3 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Amgen that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
This is a global randomized double-blind placebo-controlled study in patients with Stage IV untreated non-small cell lung cancer (NSCLC) with or without bone metastasis. Eligible participants are to receive 4 to 6 cycles of a standard of care platinum-doublet chemotherapy regimen. Participants will be randomized in a 2:1 ratio to receive denosumab or matching placebo with the first investigational product dose coinciding with participant's first cycle of chemotherapy and continuing until the primary analysis, unacceptable toxicity, withdrawal of consent, death, or lost to follow-up. Participants who discontinued the investigational product early (ie, before primary analysis) were followed for disease status and survival. The primary analysis took place when 149 events of death had been reported. All participants were followed for 2 years after the last dose of blinded investigational product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin
Exclusion Criteria:
Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, or with the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
Drug: Zoledronic acid · Drug: Placebo to Denosumab · Drug: Standard Chemotherapy
Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
Drug: Denosumab · Drug: Standard Chemotherapy · Drug: Placebo to Zoledronic Acid
Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
Also known as: XGEVA
Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Also known as: Zometa
Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Overall Survival (OS)
Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date.
Time frame: From randomization until the end of study; median time on study was 9.64 months.
Correlation of Tumor Tissue RANK Expression With Overall Survival
To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-κB (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival
To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Objective Response Rate
Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration. CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions. Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Correlation of Tumor Tissue RANK Expression With Objective Response Rate
To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Correlation of Tumor Tissue RANKL Expression With Objective Response Rate
To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Clinical Benefit Rate
Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Progression-free Survival (PFS)
Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery.
Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing
Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.
Time frame: Prior to dosing at day 8 and weeks 3, 6, 9, 12, 15, 18, 21 and 24.
Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing
Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.
Time frame: Prior to dosing at day 8 and weeks 4, 8, 12, 16, 20 and 24
Number of Participants With Treatment-emergent Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following criteria * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. Fatal adverse events include only deaths reported on the Adverse Event Case Report Form.
Time frame: From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.
This study was conducted at 57 centers in 10 countries including the United Kingdom, Netherlands, France, Italy, Germany, Czech Republic, United States, Canada, Australia and Greece. Participants were enrolled from 31 December 2013 to 21 May 2015.
| Milestone | Placebo | Denosumab |
|---|---|---|
| Started | 78 | 148 |
| Received study drug | 76 | 145 |
| Completed | 0 | 0 |
| Not completed | 78 | 148 |
| Withdrew: Death | 61 | 120 |
| Withdrew: Withdrawal by subject | 8 | 17 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Sponsor decision | 9 | 10 |
Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date.
| months | Placebo | Denosumab |
|---|---|---|
| Overall Survival (OS) | 10.9 (9.26 to 15.54) | 10.7 (8.54 to 12.35) |
To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-κB (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group.
| hazard ratio | Placebo | Denosumab |
|---|---|---|
| Cytoplasm all intensity | 0.84 (0.65 to 1.09) | 1.00 (0.85 to 1.17) |
| Membrane all intensity | 0.72 (0.51 to 1.01) | 0.92 (0.74 to 1.14) |
| Total all intensity | 0.80 (0.62 to 1.03) | 1.00 (0.85 to 1.17) |
| Cytoplasm H-score | 0.83 (0.65 to 1.07) | 1.00 (0.86 to 1.16) |
| Membrane H-score | 0.72 (0.52 to 1.00) | 0.93 (0.77 to 1.13) |
| Total H-score | 0.80 (0.62 to 1.02) | 1.00 (0.86 to 1.16) |
To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group.
| hazard ratio | Placebo | Denosumab |
|---|---|---|
| Cytoplasm all intensity | 0.77 (0.63 to 0.95) | 0.93 (0.82 to 1.05) |
| Cytoplasm H-score | 0.79 (0.66 to 0.95) | 0.93 (0.84 to 1.04) |
Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration. CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions. Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Objective Response Rate | 43.4 | 36.8 |
To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.
| odds ratio | Placebo | Denosumab |
|---|---|---|
| Cytoplasm all intensity | 1.00 (0.67 to 1.50) | 0.88 (0.68 to 1.13) |
| Membrane all intensity | 1.18 (0.74 to 1.89) | 0.82 (0.57 to 1.17) |
| Total all intensity | 1.16 (0.78 to 1.71) | 0.88 (0.68 to 1.13) |
| Cytoplasm H-score | 1.00 (0.69 to 1.47) | 0.87 (0.68 to 1.11) |
| Membrane H-score | 1.14 (0.74 to 1.76) | 0.82 (0.59 to 1.14) |
| Total H-score | 1.14 (0.79 to 1.65) | 0.87 (0.69 to 1.11) |
To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.
| odds ratio | Placebo | Denosumab |
|---|---|---|
| Cytoplasm all intensity | 1.27 (0.88 to 1.83) | 1.10 (0.90 to 1.35) |
| Cytoplasm H-score | 1.25 (0.91 to 1.72) | 1.09 (0.91 to 1.30) |
Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Clinical Benefit Rate | 53.9 | 47.9 |
Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery.
| months | Placebo | Denosumab |
|---|---|---|
| Progression-free Survival (PFS) | 5.7 (4.37 to 7.16) | 5.2 (4.24 to 5.78) |
Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.
| ng/mL | Denosumab |
|---|---|
| Dose 2 - Day 8 | 8590 ± 4080 |
| Dose 3 - Week 3 | 12200 ± 5710 |
| Dose 4 - Week 6 | 19700 ± 7350 |
| Dose 5 - Week 9 | 19600 ± 8270 |
| Dose 6 - Week 12 | 22800 ± 10400 |
| Dose 7 - Week 15 | 24300 ± 11500 |
| Dose 8 - Week 18 | 22700 ± 10600 |
| Dose 9 - Week 21 | 22100 ± 11200 |
| Dose 10 - Week 24 | 23300 ± 12700 |
Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.
| ng/mL | Denosumab |
|---|---|
| Dose 2 - Day 8 | 8990 ± 2470 |
| Dose 3 - Week 4 | 10900 ± 3170 |
| Dose 4 - Week 8 | 15700 ± 6710 |
| Dose 5 - Week 12 | 14500 ± 4940 |
| Dose 6 - Week 16 | 13000 ± 4380 |
| Dose 7 - Week 20 | 15400 ± 5620 |
| Dose 8 - Week 24 | 15900 ± 7810 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following criteria * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. Fatal adverse events include only deaths reported on the Adverse Event Case Report Form.
| participants | Placebo | Denosumab |
|---|---|---|
| All adverse events (AEs) | 76 | 144 |
| Serious adverse events | 68 | 129 |
| AEs leading to discontinuation of study drug | 6 | 20 |
| Fatal adverse events | 53 | 113 |
| Treatment-related adverse events (TRAEs) | 24 | 51 |
| Treatment-related serious adverse events | 0 | 6 |
| TRAEs leading to discontinuation of study drug | 0 | 7 |
| Treatment-related fatal adverse events | 0 | 0 |
Collected over From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 68/76 (89.5%) | 71/76 (93.4%) |
| Denosumab | — | 129/145 (89%) | 139/145 (95.9%) |
| Event | Placebo | Denosumab |
|---|---|---|
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/76 | 19/145 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/76 | 16/145 |
| PneumoniaInfections and infestations | 7/76 | 14/145 |
| Non-small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/76 | 14/145 |
| PyrexiaGeneral disorders | 2/76 | 12/145 |
| Non-small cell lung cancer stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/76 | 12/145 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/76 | 10/145 |
| AnaemiaBlood and lymphatic system disorders | 5/76 | 5/145 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/76 | 6/145 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/76 | 4/145 |
| Event | Placebo | Denosumab |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 38/76 | 60/145 |
| FatigueGeneral disorders | 33/76 | 67/145 |
| NauseaGastrointestinal disorders | 34/76 | 64/145 |
| ConstipationGastrointestinal disorders | 27/76 | 50/145 |
| Decreased appetiteMetabolism and nutrition disorders | 23/76 | 34/145 |
| VomitingGastrointestinal disorders | 14/76 | 35/145 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/76 | 35/145 |
| Oedema peripheralGeneral disorders | 17/76 | 26/145 |
| NeutropeniaBlood and lymphatic system disorders | 15/76 | 32/145 |
| ThrombocytopeniaBlood and lymphatic system disorders | 16/76 | 16/145 |
| Age, Continuous(years) | Placebo | Denosumab | Total |
|---|---|---|---|
| Mean | 64.0 ± 10.1 | 63.8 ± 9.7 | 63.8 ± 9.8 |
| Sex: Female, Male(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Female | 20 | 54 | 74 |
| Male | 58 | 94 | 152 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Black or African American | 2 | 7 | 9 |
| White or Caucasian | 73 | 133 | 206 |
| Others | 3 | 8 | 11 |
| Presence of Bone Metastasis(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 35 | 65 | 100 |
| No | 43 | 83 | 126 |
| Histology(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Squamous | 18 | 35 | 53 |
| Non-squamous | 60 | 113 | 173 |
| Geographic region(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| North America/Australia | 30 | 63 | 93 |
| Western Europe | 35 | 67 | 102 |
| Rest of World | 13 | 18 | 31 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| 0 (Fully active) | 33 | 69 | 102 |
| 1 (Restrictive but ambulatory) | 45 | 79 | 124 |
| Time from Initial Diagnosis of NSCLC to Randomization(months) | Placebo | Denosumab | Total |
|---|---|---|---|
| Mean | 2.46 ± 5.28 | 6.32 ± 16.96 | 4.99 ± 14.17 |
Ran from Dec 2013 to primary completion in Jul 2016, 30 months.
Results were first posted in Aug 2017, 1 year after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 30 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Carcinoma, Non-Small-Cell Lung →